Compare LGL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | XGN |
|---|---|---|
| Founded | 1917 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 253.9M |
| IPO Year | N/A | 2019 |
| Metric | LGL | XGN |
|---|---|---|
| Price | $5.69 | $6.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 10.5K | ★ 246.3K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 149.85 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $4,107,000.00 | ★ $63,599,000.00 |
| Revenue This Year | N/A | $22.15 |
| Revenue Next Year | N/A | $15.26 |
| P/E Ratio | $33.25 | ★ N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $5.45 | $2.67 |
| 52 Week High | $9.74 | $12.23 |
| Indicator | LGL | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 24.04 |
| Support Level | $5.50 | $6.37 |
| Resistance Level | $6.02 | $7.29 |
| Average True Range (ATR) | 0.23 | 0.34 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 35.70 | 1.63 |
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.